Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.550
-0.010 (-0.64%)
Aug 17, 2026, 12:51 PM EDT - Market open
Aldeyra Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 45.09 | 70.04 | 54.53 | 142.82 | 144.42 | 104.79 |
Short-Term Investments | - | - | 46.62 | - | 29.88 | - |
Cash & Short-Term Investments | 45.09 | 70.04 | 101.15 | 142.82 | 174.3 | 104.79 |
Cash Growth | -44.96% | -30.76% | -29.18% | -18.06% | 66.33% | 98.25% |
Other Receivables | - | - | - | - | 3.24 | 0.03 |
Receivables | - | - | - | - | 3.24 | 125.03 |
Prepaid Expenses | 1.66 | 0.7 | 0.71 | 0.52 | 0.87 | 0.53 |
Other Current Assets | 0.63 | 1.04 | 2.21 | 4.46 | 2.61 | 2.4 |
Total Current Assets | 47.38 | 71.78 | 104.07 | 147.81 | 181.02 | 232.75 |
Property, Plant & Equipment | 0.16 | 0.28 | 0.27 | 0.52 | 0.27 | 0.38 |
Long-Term Deferred Charges | - | - | 0.27 | - | - | - |
Total Assets | 47.54 | 72.06 | 104.61 | 148.33 | 181.29 | 233.14 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.14 | 0.16 | 0.18 | 1.34 | 0.13 | 1.02 |
Accrued Expenses | 3.37 | 6.12 | 12.12 | 5.54 | 14.07 | 10.52 |
Current Portion of Long-Term Debt | - | 15.25 | 0.03 | 15.15 | 0.91 | - |
Current Portion of Leases | 0.14 | 0.28 | 0.27 | 0.24 | 0.25 | 0.23 |
Current Unearned Revenue | 6 | 6 | 6 | - | - | - |
Total Current Liabilities | 9.66 | 27.81 | 18.6 | 22.26 | 15.36 | 11.77 |
Long-Term Debt | - | - | 15 | - | 14.92 | 15.5 |
Long-Term Leases | - | - | - | 0.27 | - | 0.13 |
Long-Term Unearned Revenue | - | - | - | 6 | - | - |
Total Liabilities | 9.66 | 27.81 | 33.6 | 28.53 | 30.28 | 27.4 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Additional Paid-In Capital | 530.69 | 528.15 | 521.02 | 513.99 | 507.77 | 500.37 |
Retained Earnings | -492.86 | -483.96 | -450.11 | -394.26 | -356.72 | -294.69 |
Comprehensive Income & Other | - | - | 0.04 | - | -0.1 | - |
Shareholders' Equity | 37.89 | 44.25 | 71 | 119.8 | 151.01 | 205.74 |
Total Liabilities & Equity | 47.54 | 72.06 | 104.61 | 148.33 | 181.29 | 233.14 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.14 | 15.53 | 15.3 | 15.66 | 16.08 | 15.86 |
Net Cash (Debt) | 44.95 | 54.51 | 85.85 | 127.17 | 158.22 | 88.93 |
Net Cash Growth | -32.27% | -36.50% | -32.49% | -19.63% | 77.91% | 136.96% |
Net Cash Per Share | 0.75 | 0.91 | 1.44 | 2.16 | 2.71 | 1.65 |
Filing Date Shares Outstanding | 60.33 | 60.18 | 59.71 | 58.9 | 58.58 | 58.1 |
Total Common Shares Outstanding | 60.32 | 60.16 | 59.65 | 59.2 | 58.56 | 58.08 |
Working Capital | 37.72 | 43.97 | 85.47 | 125.55 | 165.66 | 220.98 |
Book Value Per Share | 0.63 | 0.74 | 1.19 | 2.02 | 2.58 | 3.54 |
Tangible Book Value | 37.89 | 44.25 | 71 | 119.8 | 151.01 | 205.74 |
Tangible Book Value Per Share | 0.63 | 0.74 | 1.19 | 2.02 | 2.58 | 3.54 |